KR960028919A - 당 피막으로부터 스테로이드의 조절된 방출 - Google Patents

당 피막으로부터 스테로이드의 조절된 방출 Download PDF

Info

Publication number
KR960028919A
KR960028919A KR1019960000693A KR19960000693A KR960028919A KR 960028919 A KR960028919 A KR 960028919A KR 1019960000693 A KR1019960000693 A KR 1019960000693A KR 19960000693 A KR19960000693 A KR 19960000693A KR 960028919 A KR960028919 A KR 960028919A
Authority
KR
South Korea
Prior art keywords
sucrose
saccharide
lactose
steroid hormone
microcrystalline cellulose
Prior art date
Application number
KR1019960000693A
Other languages
English (en)
Other versions
KR100338581B1 (ko
Inventor
죠셉 바콤 레지날드
Original Assignee
이곤 이. 버그
아메리칸 홈 프로덕츠 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23473354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR960028919(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 이곤 이. 버그, 아메리칸 홈 프로덕츠 코포레이션 filed Critical 이곤 이. 버그
Publication of KR960028919A publication Critical patent/KR960028919A/ko
Application granted granted Critical
Publication of KR100338581B1 publication Critical patent/KR100338581B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 당, 투여량의 스테로이드 호르몬 및 스테로이드 방출 속도 조절량의 미소결정질 셀룰로오즈를 함유하는 의약용 압축 정제에 적용하기 위한 당 피복 조성물에 관한 것이다.

Description

당 피막으로부터 스테로이드의 조절된 방출
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 당, 투여 용량의 스테로이드 호르몬 및 스테로이드 방출 속도 조절량의 미소결정질 셀룰로오즈를 함유하는 압축된 의약용 정제에 적용하기 위한 당 피복 조성물.
  2. 제1항에 있어서, 당이 슈크로오즈인 당 피복 조성물.
  3. 제1항에 있어서, 스테로이드 호르몬이 메드록시프로게스터론 아세테이트, 레보노르게스트렐, 게스토덴, 메드로게스톤,에스트라디올, 에스트리올, 에틴닐에스트라디올, 메스트라놀, 에스트론, 디엔에스트롤, 헥세스트롤, 디에틸스틸베스트롤, 프로게스테론, 데소게스트렐, 노르게스티메이트, 하이드록시프로게스테론, 노르에틴드론, 노르에틴돈 아세테이트, 노르게스트렐, 메게스트롤 아세테이트, 메틸스토스테론, 에틸에스트레놀, 메탄디에논, 옥산드롤론 또는 트리메게스톤인 당 피복 조성물.
  4. 제1항에 있서, 슈크로오즈, 약 0.1중량% 내지 약 3중량%의 미소결정질 셀룰로오즈, 0 내지 약 5중량%의 폴리비닐피롤리돈, 약 0.1 내지 약 20중량%의 스테로이드 호르몬 및 수용액을 함유하는 당 피복 조성물.
  5. 배합된 에스트로겐을 함유하는 정제 코어, 및 스테로이드 호르몬과 방출 속도 조절량의 미소결정질 셀룰로오즈를 함유한 당 피막을 포함하는 압축 정제.
  6. 제5항에 있어서, 정제 코어가 배합된 에스트로겐 약 0.1 내지 약 5.0㎎을 함유하고 당 피막이 스테로이드 호르몬 약 1.0 내지 약 50㎎을 함유하는 압축 정제.
  7. 제5항에 있어서, 정제 코어가 배합된 에스트로겐 약 0.3 내지 약 2.5㎎을 함유하고 당 피막이 메드록시프로게스테론 아세테이트 약 1.5 내지 약 30㎎을 함유하는 압축 정제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960000693A 1995-01-17 1996-01-16 스테로이드의제어방출용당의조성물및이를함유하는압축정제 KR100338581B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/373,667 US5547948A (en) 1995-01-17 1995-01-17 Controlled release of steroids from sugar coatings
US08/373,667 1995-01-17

Publications (2)

Publication Number Publication Date
KR960028919A true KR960028919A (ko) 1996-08-17
KR100338581B1 KR100338581B1 (ko) 2002-11-23

Family

ID=23473354

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960000693A KR100338581B1 (ko) 1995-01-17 1996-01-16 스테로이드의제어방출용당의조성물및이를함유하는압축정제

Country Status (35)

Country Link
US (2) US5547948A (ko)
EP (1) EP0722720B1 (ko)
JP (1) JP3833292B2 (ko)
KR (1) KR100338581B1 (ko)
CN (1) CN1106839C (ko)
AR (1) AR002019A1 (ko)
AT (1) ATE185482T1 (ko)
AU (1) AU705879B2 (ko)
BR (1) BR9600100B1 (ko)
CA (1) CA2167254A1 (ko)
CO (1) CO4370096A1 (ko)
CZ (1) CZ286102B6 (ko)
DE (1) DE69604600T2 (ko)
DK (1) DK0722720T3 (ko)
EE (1) EE03802B1 (ko)
EG (1) EG23687A (ko)
ES (1) ES2137627T3 (ko)
FI (1) FI117592B (ko)
GR (1) GR3031920T3 (ko)
HK (1) HK1009935A1 (ko)
HU (1) HU223781B1 (ko)
ID (1) ID23996A (ko)
IL (1) IL116772A (ko)
IS (1) IS1878B (ko)
MY (1) MY115786A (ko)
NO (1) NO315307B1 (ko)
NZ (1) NZ280826A (ko)
PL (1) PL183330B1 (ko)
RU (1) RU2152207C1 (ko)
SI (1) SI0722720T1 (ko)
SK (1) SK280484B6 (ko)
TR (1) TR199600038A2 (ko)
TW (1) TW460301B (ko)
UA (1) UA37236C2 (ko)
ZA (1) ZA96301B (ko)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547948A (en) * 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings
US5759577A (en) * 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US6479475B1 (en) * 1996-07-26 2002-11-12 Wyeth Oral contraceptive
US6451778B1 (en) * 1996-07-26 2002-09-17 Wyeth Oral contraceptive
CA2230748C (en) * 1997-03-14 2010-08-03 American Home Products Corporation Rapamycin formulations for oral administration
DE19715594A1 (de) 1997-04-15 1998-10-22 Bayer Ag Analgetika-Kombination
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
ATE283687T1 (de) * 1997-06-13 2004-12-15 Wyeth Corp Rapamycin-formulierungen zur oralen verabreichung
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
US6432448B1 (en) * 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
FR2801218B1 (fr) * 1999-11-23 2001-12-28 Hoechst Marion Roussel Inc Compositions pharmaceutiques comprenant de la trimegestone, leurs procedes de preparation ainsi que le conditionnement primaire les renfermant
AT500063A1 (de) 1999-11-23 2005-10-15 Sandoz Ag Beschichtete tablettenkerne
US6660726B2 (en) 2000-03-10 2003-12-09 Endeavor Pharmaceuticals Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
US7989436B2 (en) 2003-07-23 2011-08-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and pharmaceutical formulations comprising the same
US7459445B2 (en) * 2000-03-10 2008-12-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and topical pharmaceutical formulations of the same
US6855703B1 (en) 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
US20010034340A1 (en) * 2000-03-20 2001-10-25 American Home Products Corporation Hormone replacement therapy
TR200300731T2 (tr) 2000-11-28 2004-08-23 Fmc Corporation Yenebilir PGA kaplama bileşimi
US6630166B1 (en) * 2001-02-12 2003-10-07 Watson Pharmaceuticals, Inc. Compositions for conjugated estrogens and associated methods
US7303763B2 (en) * 2001-02-12 2007-12-04 Watson Laboratories, Inc. Compositions for conjugated estrogens and associated methods
JP2004533419A (ja) * 2001-03-16 2004-11-04 ワイス ホルモン補充療法
BR0208165A (pt) * 2001-03-16 2004-03-30 Wyeth Corp Composições farmacêuticas e seus usos na terapia de reposição de estrogênio
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
TW200306196A (en) * 2002-04-03 2003-11-16 Wyeth Corp Hormone replacement therapy
TW200306846A (en) * 2002-04-03 2003-12-01 Wyeth Corp Hormone replacement therapy
TW200306851A (en) * 2002-04-29 2003-12-01 Wyeth Corp Hormone replacement therapy
TW200400040A (en) * 2002-05-17 2004-01-01 Wyeth Corp Hormone replacement therapy
US6992075B2 (en) * 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
EP1622623A4 (en) * 2003-04-11 2009-03-18 Barr Lab Inc METHOD FOR THE ADMINISTRATION OF ESTROGENIC AND TESTED
JP4880465B2 (ja) * 2003-09-29 2012-02-22 ノボ・ノルディスク・フェムケア・アーゲー 向上した安定性のプロゲストーゲン製剤
PE20060245A1 (es) * 2004-06-07 2006-05-03 Wyeth Corp Recubrimientos de azucar y metodos para la fabricacion de los mismos
MX2007003519A (es) * 2004-09-23 2007-08-07 Fmc Corp Composicion de recubrimiento.
WO2006084082A1 (en) * 2005-02-03 2006-08-10 Duramed Pharmaceuticals, Inc. Compositions of unconjugated estrogens and methods for their use
WO2007002823A2 (en) * 2005-06-29 2007-01-04 Wyeth Formulations of conjugated estrogens and bazedoxifene
BRPI0718558A2 (pt) * 2006-11-07 2013-11-19 Wyeth Corp Forma de dosagem sólida, composição aquosa, método para preparar uma forma de dosagem sólida, e, produto
JP2010511062A (ja) * 2006-11-29 2010-04-08 ワイス エルエルシー エストロゲン／ｓｅｒｍおよびエストロゲン／プロゲスチン二層錠剤
WO2012120365A1 (en) 2011-03-07 2012-09-13 Aurobindo Pharma Limited Stable pharmaceutical composition comprising ethinyl estradiol
BR112013029199B1 (pt) * 2011-05-13 2022-02-08 Eb Ip Hybritabs B.V. Dispositivo de distribuição de dois fármacos
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP2970839B1 (en) * 2013-03-15 2017-02-22 Monosol, LLC Water-soluble film for delayed release
US10808210B2 (en) 2013-03-15 2020-10-20 Monosol, Llc Water-soluble film for delayed release
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
MX2018011705A (es) 2016-04-01 2019-06-10 Therapeuticsmd Inc Composicion farmaceutica de hormona esteroide.
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN116236453A (zh) * 2023-02-08 2023-06-09 江苏和汇医药科技有限公司 一种延长药品释放的糖包衣及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB844772A (en) * 1956-04-19 1960-08-17 Pfizer & Co C Granular pharmaceutical compositions and process for preparing same
GB888631A (en) * 1959-02-24 1962-01-31 Upjohn Co Improvements in or relating to oral therapeutic compositions comprising steroids
FR1396710A (fr) * 1964-06-15 1965-04-23 Diwag Chemische Fabriken G M B Procédé pour la fabrication de charges ou supports perfectionnés et produits obtenus
US3980766A (en) * 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
US4248856A (en) * 1979-07-10 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4309404A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4327076A (en) * 1980-11-17 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
US4425339A (en) * 1981-04-09 1984-01-10 Syntex (U.S.A.) Inc. Treatment of menopausal symptoms
US4415546A (en) * 1981-05-12 1983-11-15 Janakiraman Ramachandran Biologically active analogs of ACTH and radioimmuno assay therefor
US4390531A (en) * 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
JPS604120A (ja) * 1983-06-22 1985-01-10 Shionogi & Co Ltd 作用持続型ピナシジル製剤
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
GB8403360D0 (en) * 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
EP0153105B1 (en) * 1984-02-10 1992-09-09 Benzon Pharma A/S Diffusion coated multiple-units dosage form
GB8414221D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Unit dosage form
SE8404467D0 (sv) * 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
US4755386A (en) * 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
GB8705083D0 (en) * 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
US4927816A (en) * 1987-08-20 1990-05-22 Ester George C Formulae and methods for sublingual ingestion of natural progesterone
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
JP2542122B2 (ja) * 1990-04-18 1996-10-09 旭化成工業株式会社 球状核、球形顆粒およびその製造方法
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5223268A (en) * 1991-05-16 1993-06-29 Sterling Drug, Inc. Low solubility drug-coated bead compositions
WO1994018951A1 (en) * 1993-02-23 1994-09-01 Warner-Lambert Company A process for the preparation of substantially alcohol free pharmaceutical compositions
ZA949929B (en) * 1993-12-23 1995-08-23 Akzo Nobel Nv Sugar-coated pharmaceutical dosage unit.
US5547948A (en) * 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings

Also Published As

Publication number Publication date
CN1106839C (zh) 2003-04-30
AR002019A1 (es) 1998-01-07
EP0722720B1 (en) 1999-10-13
EG23687A (en) 2007-05-13
HU223781B1 (hu) 2005-01-28
ES2137627T3 (es) 1999-12-16
FI960210A (fi) 1996-07-18
IL116772A (en) 1999-08-17
HK1009935A1 (en) 1999-06-11
CZ286102B6 (cs) 2000-01-12
PL183330B1 (pl) 2002-06-28
PL312336A1 (en) 1996-07-22
NO315307B1 (no) 2003-08-18
ZA96301B (en) 1997-07-15
BR9600100B1 (pt) 2009-01-13
CO4370096A1 (es) 1996-10-07
IL116772A0 (en) 1996-05-14
ID23996A (id) 1996-07-25
CN1141168A (zh) 1997-01-29
HUP9600090A2 (en) 1996-12-30
AU4098296A (en) 1996-07-25
JP3833292B2 (ja) 2006-10-11
BR9600100A (pt) 1998-01-27
TW460301B (en) 2001-10-21
SI0722720T1 (en) 1999-12-31
UA37236C2 (uk) 2001-05-15
US5759576A (en) 1998-06-02
CA2167254A1 (en) 1996-07-18
CZ12896A3 (en) 1996-08-14
FI960210A0 (fi) 1996-01-16
EE03802B1 (et) 2002-08-15
GR3031920T3 (en) 2000-03-31
NO960191L (no) 1996-07-18
JPH08231436A (ja) 1996-09-10
DE69604600D1 (de) 1999-11-18
FI117592B (fi) 2006-12-15
EP0722720A1 (en) 1996-07-24
SK4996A3 (en) 1997-04-09
NZ280826A (en) 1996-12-20
AU705879B2 (en) 1999-06-03
TR199600038A2 (tr) 1996-08-21
DE69604600T2 (de) 2000-02-24
IS1878B (is) 2003-06-20
HUP9600090A3 (en) 1997-05-28
SK280484B6 (sk) 2000-02-14
DK0722720T3 (da) 2000-01-03
IS4318A (is) 1996-07-18
RU2152207C1 (ru) 2000-07-10
ATE185482T1 (de) 1999-10-15
EE9600002A (et) 1996-08-15
NO960191D0 (no) 1996-01-16
MY115786A (en) 2003-09-30
KR100338581B1 (ko) 2002-11-23
US5547948A (en) 1996-08-20

Similar Documents

Publication Publication Date Title
KR960028919A (ko) 당 피막으로부터 스테로이드의 조절된 방출
KR970069031A (ko) 당 제피로부터 스테로이드의 방출이 조절되는 약제학적 정제
US5633242A (en) Pharmaceuticals for contraception/hormone substitution containing a biogenous estrogen component
AU620940B2 (en) Contraception system and method
Sitruk-Ware et al. Nestorone®: clinical applications for contraception and HRT
AU716249B2 (en) Contraceptive process and kit for female mammals that consists of a combination of gestagen and estrogen
EP0912186B1 (en) Progestogen-anti-progestogen regimens
KR920011517A (ko) 저에스트로겐 경구 피임제
NO179311B (no) Flerfasekombinasjons- og kontraseptiv pakke
RU97100300A (ru) Контролируемое освобождение стероидов из сахарных покрытий
CA2267743A1 (en) Low dose estrogen interrupted hormone replacement therapy
RU98101254A (ru) Фармацевтический комбинированный препарат, комплект инструмента и метод гормональной контрацепции
KR970704450A (ko) 자궁내막증식증 또는 자궁평활근종을 치료하기 위한 프로게스테론 길항제 및 게스타겐의 용도(Use of a Progesterone Antagonist and of a Gestagen for the Treatment of Endometriosis or Leiomyomate Uteri)
HU213408B (en) Process for producing pharmaceutical compositions comprising drospirenon
CA2420292A1 (en) Contraception process and administration form for the same
US20030078245A1 (en) Progestogen-anti-progestogen regimens
HUT77610A (hu) Ösztra-1,3,5(10)-trién-származékok, eljárás azok előállítására és az azokat tartalmazó gyógyászati készítmények
CN101189015A (zh) 延长的雌激素定量给药避孕疗法
EP2285383A2 (de) Sequentielle verarbeitung von 20,20,21,21-pentafluor-17-hydroxy-11 -ý4-(hydroxyacetyl) phenyl¨-19-nor-17 -pregna-4,9-dien-3-on und einem oder mehreren gestagenen zur behandlung gynäkologischer erkrankungen
US20050064031A1 (en) Combination contraceptive, kits that contain the latter, and a method that uses the latter
NZ307178A (en) Medicament for contraception; contains two, separately packed, sequential hormonal components
Philibert et al. 204. RU 38486—A potent antiprogesterone
US4171358A (en) Novel contraceptive method
CA2410993A1 (en) Starter kit for low dose oral contraceptives
CN1281363A (zh) 孕激素-抗孕激素体系

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130429

Year of fee payment: 12

FPAY Annual fee payment

Payment date: 20140430

Year of fee payment: 13

EXPY Expiration of term